Search results
Treatment is directed at alleviating organ dysfunction, preventing irreversible scarring, and improving quality of life. Herein, we review the indications for treatment, pharmacotherapy, treatment duration, side effects, adjunct non-pharmacologic therapies, and outcomes for patients.
22 sty 2024 · In this study, the association and causality of 5 kinds of blood glucose and lipid traits (fasting glucose, HDLC, LDLC, TC, and TG) with sarcoidosis was evaluated by retrospective observational study and MR analysis, respectively.
Oral glucocorticoids can be tapered over 6 to 18 months if symptoms, pulmonary function test results, and radiographs improve. Prolonged use of oral glucocorticoids may be required to control symptoms and stabilize disease.
29 lis 2022 · Sarcoidosis is a heterogeneous disease with variable organ involvement, disease course, and response to treatment. We offer an angle on when and how to treat, and provide an overall roadmap for managing sarcoidosis. Similar content being viewed by others. Introduction. Sarcoidosis is a very old disease.
19 gru 2023 · Although this trial suggests that there may be a role for rituximab in treatment for refractory pulmonary sarcoidosis, more data are needed in order to determine whether it represents an efficacious treatment option.
24 maj 2021 · Sarcoidosis is associated with an increased risk of T2D especially in older, male, corticosteroid-treated patients at diagnosis. Screening for T2D for these patients is advisable.
18 lut 2019 · Key messages. This study provides detailed information on how the first set of patient-centred outcomes in patients with a diagnosis of pulmonary sarcoidosis was developed. The international process resulted in a consensus-driven recommended set.
